Fundraising FoxHatteras Venture Partners — 2022 Investments
8 investments dated 2022 · listed companies and verified rows first · show all
Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions.
BiotechDigital HealthChapel Hill, US
Jenny Ting(Director and Co-founder)Matthew Cohen(Director)Lev Osherovich(Director)Mark Vellaca(Director)Anil Goyal(CEO and Director)
BoardBenjamin Scruggs(Director)
Board seatMark Velleca· per SEC Form D
Co-investorsDelin VenturesOUP (Osage University Partners)
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan(Co-founder, Chief Scientific Officer)inAndrew Carek(Co-founder, Chief Technical Officer)inEric Meizlish(Chief Executive Officer)inJohn D. Martin(Chief Medical Officer)in
Board seatLauren Pierce Flickinger· per SEC Form D
Co-investorsBayMed Venture PartnersBroadview VenturesCross-Border Impact VenturesLaerdal Million Lives FundOSF VenturesPortal Innovations+1 more
HealthtechBurlington, US
Artur Adib(CEO)inTim Wall(Director)
Co-investorsBreyer CapitalDudley FundY Combinator1984 Ventures Management, LlcAltaclub VCAltaIR Capital+6 more
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesJDRF T1D FundNorthpond VenturesTakeda Ventures+1 more
Entegrion develops a point-of-care viscoelastic coagulation monitoring system (VCM) for rapid hemostasis assessment in clinical settings including trauma, surgery, and obstetrics.
BiotechDefense TechHealthtechMedical DevicesDurham, US
Bert Valada(President and CEO)inRichard Martin(Executive Officer)Susan Reyer(Executive Officer)Michael Galiger(Executive Officer)John Mowell(Director)Thomas Edwards(Director)
Roobrik provides science-based online surveys, financial-readiness assessments, and chat tools that help prospective senior living residents and their families evaluate their options while converting more website visitors into qualified leads for senior living providers.
Digital HealthHealthtechMarketing TechSaaSSales TechGreensboro, US
Nate O'Keefe(Founder)inJudith Conaway(Executive Officer)David Levin(Director)inMaureen O'Connor(Director)William Clark(Director)
Co-investorsJurassic CapitalNC IDEAThe Launch PlaceThird Act Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Syntheon 2.0Vircho Health
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.